Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03660592 |
Other study ID # |
LUS/HF |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 1, 2016 |
Est. completion date |
January 1, 2017 |
Study information
Verified date |
March 2022 |
Source |
University of Monastir |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Discrimination between cardiac and non-cardiac causes of dyspnea can be challenging, causing
excessive delay before adequate therapy. In clinical practice lung ultrasound (LUS) is
becoming an easy and reliable noninvasive tool for the evaluation of dyspnea and can shorten
the time to diagnosis .However the reproductibility of this test was not extensively studied.
Description:
Dyspnea is one of the most distressing situations for the patient . Emergency cases do not
always present in conditions that are ideal for immediate diagnosis, which sometimes
compromises outcome. Physical examination, laboratory findings and radiography are imperfect,
resulting in a need for sophisticated test results that delay management.
Lung ultrasonography is becoming a standard tool in critical cases in the ED.
the investigators aim to perform ultrasonography on consecutive patients admitted to the ICU
with dyspnea, comparing lung ultrasonography results on initial presentation with the final
diagnosis by the ICU team.
Three items were assessed: artifacts (horizontal A lines or vertical B lines indicating
interstitial syndrome), lung sliding, and alveolar consolidation and/or pleural effusion,
these items were grouped to assess ultrasound profiles.
This study assesses the potential of lung ultrasonography to diagnose heart failure.The
second aim of this study was to evaluate the inter-observer reproducibility of LUS performed
by ED residents in the evaluation of cardiac causes of acute dyspnea.
Patients presenting to the ED with acute dyspnea will be prospectively enrolled in this
study. In each patient, LUS was performed by two ED residents blinded to clinical diagnoses.
AHF was determined on the base of clinical exam, chest x-ray , brain natriuretic peptide
(BNP) and echocardiographic findings.
A patient lung comet score (LCS) was obtained by summing the number of comets in each of the
scanned spaces.
Then the probability of AHF was defined as :
low probability (LCS<15) intermediate probability (15 30
).